Human uPAR Quantikine ELISA Kit

Catalog # Availability Size / Price Qty
Control Products Available
Human uPAR ELISA Standard Curve
2 Images
Product Details
Citations (42)
Supplemental Products

Human uPAR Quantikine ELISA Kit Summary

Assay Type
Solid Phase Sandwich ELISA
96-well strip plate
Assay Length
4.5 hours
Sample Type & Volume Required Per Well
Cell Culture Supernates (10 uL), Serum (10 uL), EDTA Plasma (10 uL), Heparin Plasma (10 uL), Urine (10 uL)
33 pg/mL
Assay Range
62.5 - 4,000 pg/mL (Cell Culture Supernates, Serum, EDTA Plasma, Heparin Plasma, Urine)
Natural and recombinant human uPAR
< 0.5% cross-reactivity observed with available related molecules.< 50% cross-species reactivity observed with species tested.
Interference observed with 1 or more available related molecules.

Product Summary

The Quantikine Human uPAR Immunoassay is a 4.5 hour solid-phase ELISA designed to measure human uPAR in cell culture supernates, serum, plasma, and urine. It contains NS0-expressed recombinant human uPAR and antibodies raised against the recombinant factor. It has been shown to accurately quantitate the recombinant factor. Results obtained using natural human uPAR showed linear curves that were parallel to the standard curves obtained using the Quantikine kit standards. These results indicate that this kit can be used to determine relative mass values of natural human uPAR.


Intra-Assay Precision (Precision within an assay) Three samples of known concentration were tested on one plate to assess intra-assay precision
Inter-Assay Precision (Precision between assays) Three samples of known concentration were tested in separate assays to assess inter-assay precision

Cell Culture Supernates, Serum, EDTA Plasma, Heparin Plasma, Urine

Intra-Assay Precision Inter-Assay Precision
Sample 1 2 3 1 2 3
n 20 20 20 40 40 40
Mean (pg/mL) 836 1593 2412 796 1546 2300
Standard Deviation 17.3 65.4 181 44.3 78.9 136
CV% 2.1 4.1 7.5 5.6 5.1 5.9


To assess the linearity of the assay, samples spiked with high concentrations of uPAR were diluted with Calibrator Diluent to produce samples with values within the dynamic range of the assay.
Human uPAR ELISA Linearity

Scientific Data

Human uPAR ELISA Standard Curve

Product Datasheets

You must select a language.


Preparation and Storage

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Store the unopened product at 2 - 8 °C. Do not use past expiration date.

Background: uPAR

The urokinase-type Plasminogen Activator Receptor (uPAR) is a GPI-anchored protein that binds to both the inactive and active forms of uPA. This interaction serves to localize and enhance the proteolytic activity of uPA, leading to increased conversion of Plasminogen to Plasmin. uPA also triggers uPAR-mediated signal transduction, activation of protein tyrosine kinases, gene expression, cell adhesion, and chemotaxis. uPAR can additionally regulate cell adhesion by direct binding to Vitronectin and preventing Integrins from binding to their ligands.

Long Name:
Urokinase-type Plasminogen Activator Receptor
Entrez Gene IDs:
5329 (Human); 18793 (Mouse); 102139334 (Cynomolgus Monkey)
Alternate Names:
CD87 antigen; CD87; Monocyte activation antigen Mo3; plasminogen activator, urokinase receptor; PLAUR; uPAR; U-PAR; UPARurokinase plasminogen activator surface receptor; u-plasminogen activator receptor form 2; URKRMO3
⚠ WARNING: This product can expose you to chemicals including N,N-Dimethylforamide, which is known to the State of California to cause cancer. For more information, go to

Assay Procedure

Refer to the product for complete assay procedure.

Bring all reagents and samples to room temperature before use. It is recommended that all samples, standards, and controls be assayed in duplicate.
  1.   Prepare all reagents, standard dilutions, and samples as directed in the product insert.
  2.   Remove excess microplate strips from the plate frame, return them to the foil pouch containing the desiccant pack, and reseal.

  3. 100 µL Assay Diluent
  4.   Add 100 µL of Assay Diluent to each well.

  5. 50 µL Standard, Control, or Sample
  6.   Add 50 µL of Standard, control, or sample to each well. Cover with a plate sealer, and incubate at room temperature for 2 hours.
  7.   Aspirate each well and wash, repeating the process 3 times for a total of 4 washes.

  8. 200 µL Conjugate
  9.   Add 200 µL of Conjugate to each well. Cover with a new plate sealer, and incubate at room temperature for 2 hours.
  10.   Aspirate and wash 4 times.

  11. 200 µL Substrate Solution
  12.   Add 200 µL Substrate Solution to each well. Incubate at room temperature for 30 minutes. PROTECT FROM LIGHT.

  13. 50 µL Stop Solution
  14.   Add 50 µL of Stop Solution to each well. Read at 450 nm within 30 minutes. Set wavelength correction to 540 nm or 570 nm.

Citations for Human uPAR Quantikine ELISA Kit

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

42 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Soluble urokinase-type plasminogen activator receptor (suPAR) is elevated in caregivers of patients with parkinsonism
    Authors: J Joyce, N Cabanas, R Pisharody, B Ouyang, R Patel, J Reiser, DA Hall, N Witek
    Parkinsonism & related disorders, 2022;101(0):39-42.
    Species: Human
    Sample Types: Serum
  2. Efficacy of Rituximab in Treatment-Resistant Focal Segmental Glomerulosclerosis With Elevated Soluble Urokinase-Type Plasminogen Activator Receptor and Activation of Podocyte beta3 Integrin
    Authors: MA Hladunewic, D Cattran, SM Sethi, SS Hayek, J Li, C Wei, SI Mullin, HN Reich, J Reiser, FC Fervenza
    Kidney international reports, 2022;7(1):68-77.
    Species: Human
    Sample Types: Serum
  3. Prospective associations between neighborhood violence and monocyte pro-inflammatory transcriptional activity in children
    Authors: GE Miller, E Chen, E Finegood, D Shimbo, SW Cole
    Brain, Behavior, and Immunity, 2021;100(0):1-7.
    Species: Human
    Sample Types: Serum
  4. Circulating levels of tight junction proteins in multiple sclerosis: Association with inflammation and disease activity before and after disease modifying therapy
    Authors: A Olsson, S Gustavsen, AR Langkilde, TH Hansen, F Sellebjerg, H Bach Sønde, AB Oturai
    Multiple sclerosis and related disorders, 2021;54(0):103136.
    Species: Human
    Sample Types: Serum
  5. Biomarkers of systemic inflammation, soluble IL-2Ralpha and the multiple sclerosis-associated IL2RA SNP rs2104286 in healthy subjects and multiple sclerosis patients
    Authors: S Buhelt, HB Søndergaar, MR Mahler, S Cobanovic, L Börnsen, C Ammitzbøll, AB Oturai, F Sellebjerg
    Multiple sclerosis and related disorders, 2021;54(0):103140.
    Species: Human
    Sample Types: Serum
  6. Salvianolic acid A attenuates steroid resistant nephrotic syndrome through suPAR/uPAR-&alphav&beta3 signaling Inhibition
    Authors: X Li, D Qi, MY Wang, K Ji, QL Xie, Y Wang, SH Du, HY Fan
    Journal of ethnopharmacology, 2021;279(0):114351.
    Species: Human
    Sample Types: Cell Culture Supernates
  7. Soluble urokinase-type plasminogen activator receptor (suPAR) is a risk indicator for eGFR loss in kidney transplant recipients
    Authors: U Jehn, K Schütte-Nü, U Henke, H Pavenstädt, B Suwelack, S Reuter
    Scientific Reports, 2021;11(1):3713.
    Species: Human
    Sample Types: Plasma
  8. Biomarkers of inflammation and epithelial barrier function in multiple sclerosis
    Authors: A Olsson, S Gustavsen, IC Hasselbalc, AR Langkilde, F Sellebjerg, AB Oturai, HB Søndergaar
    Mult Scler Relat Disord, 2020;46(0):102520.
    Species: Human
    Sample Types: Serum
  9. The Plasma Soluble Urokinase Plasminogen Activator Receptor Is Related to Disease Activity of Patients with ANCA-Associated Vasculitis
    Authors: F Huang, Y Li, R Xu, A Cheng, Y Lv, Q Liu
    Mediators Inflamm., 2020;2020(0):7850179.
    Species: Human
    Sample Types: Plasma
  10. The Marker of Tubular Injury, Kidney Injury Molecule-1 (KIM-1), in Acute Kidney Injury Complicating Acute Pancreatitis: A Preliminary Study
    Authors: J Wajda, P Dumnicka, W Kolber, M Sporek, B Maziarz, P Ceranowicz, M Ku?niewski, B Ku?nierz-C
    J Clin Med, 2020;9(5):.
    Species: Human
    Sample Types: Serum
  11. Diagnostic and Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) in Focal Segmental Glomerulosclerosis and Impact of Detection Method
    Authors: W Winnicki, G Sunder-Pla, G Sengölge, A Handisurya, H Herkner, C Kornauth, B Bielesz, L Wagner, Ž Kiki?, S Pajenda, T Reiter, B Schairer, A Schmidt
    Sci Rep, 2019;9(1):13783.
    Species: Human
    Sample Types: Plasma
  12. Phase 1 trial of intrapleural LTI-01; single chain urokinase in complicated parapneumonic effusions or empyema
    Authors: L Beckert, B Brockway, G Simpson, AM Southcott, YCG Lee, N Rahman, RW Light, S Shoemaker, J Gillies, AA Komissarov, G Florova, T Ochran, W Bradley, H Ndetan, KP Singh, K Sarva, S Idell
    JCI Insight, 2019;5(0):.
  13. Urinary myo-inositol is associated with the clinical outcome in focal segmental glomerulosclerosis
    Authors: JN An, JS Hyeon, Y Jung, YW Choi, JH Kim, SH Yang, S Oh, S Kwon, SH Lee, JH Cho, SH Park, H Ha, DK Kim, JP Lee, GS Hwang
    Sci Rep, 2019;9(1):14707.
    Species: Human
    Sample Types: Plasma
  14. Gut microbiome-derived phenyl sulfate contributes to albuminuria in diabetic kidney disease
    Authors: K Kikuchi, D Saigusa, Y Kanemitsu, Y Matsumoto, P Thanai, N Suzuki, K Mise, H Yamaguchi, T Nakamura, K Asaji, C Mukawa, H Tsukamoto, T Sato, Y Oikawa, T Iwasaki, Y Oe, T Tsukimi, NN Fukuda, HJ Ho, F Nanto-Hara, J Ogura, R Saito, S Nagao, Y Ohsaki, S Shimada, T Suzuki, T Toyohara, E Mishima, H Shima, Y Akiyama, Y Akiyama, M Ichijo, T Matsuhashi, A Matsuo, Y Ogata, CC Yang, C Suzuki, MC Breeggeman, J Heymann, M Shimizu, S Ogawa, N Takahashi, T Suzuki, Y Owada, S Kure, N Mano, T Soga, T Wada, JB Kopp, S Fukuda, A Hozawa, M Yamamoto, S Ito, J Wada, Y Tomioka, T Abe
    Nat Commun, 2019;10(1):1835.
    Species: Human
    Sample Types: Plasma
  15. Serum Urokinase-Type Plasminogen Activator Receptor Does Not Outperform C-Reactive Protein and Procalcitonin as an Early Marker of Severity of Acute Pancreatitis
    Authors: W Kolber, B Ku?nierz-C, P Dumnicka, M Maraj, M Mazur-Lask, M P?dziwiatr, P Ceranowicz
    J Clin Med, 2018;7(10):.
    Species: Human
    Sample Types: Serum
  16. Fetal Renal Echogenicity Associated with Maternal Focal Segmental Glomerulosclerosis: The Effect of Transplacental Transmission of Permeability Factor suPAR
    Authors: S Shuster, G Ankawi, C Licht, J Reiser, X Wang, C Wei, D Chitayat, M Hladunewic
    J Clin Med, 2018;7(10):.
    Species: Human
    Sample Types: Serum
  17. Soluble Urokinase Plasminogen Activator Receptor (suPAR) and All-Cause and Cardiovascular Mortality in Diverse Hemodialysis Patients
    Authors: C Torino, P Pizzini, S Cutrupi, M Postorino, G Tripepi, F Mallamaci, J Reiser, C Zoccali,
    Kidney Int Rep, 2018;3(5):1100-1109.
    Species: Human
    Sample Types: Serum
  18. Predicting Mortality in African Americans With Type 2 Diabetes Mellitus: Soluble Urokinase Plasminogen Activator Receptor, Coronary Artery Calcium, and High-Sensitivity C-Reactive Protein
    Authors: SS Hayek, J Divers, M Raad, J Xu, DW Bowden, M Tracy, J Reiser, BI Freedman
    J Am Heart Assoc, 2018;7(9):.
    Species: Human
    Sample Types: Plasma
  19. Serum suPAR and syndecan-4 levels predict severity of community-acquired pneumonia: a prospective, multi-centre study
    Authors: Q Luo, P Ning, Y Zheng, Y Shang, B Zhou, Z Gao
    Crit Care, 2018;22(1):15.
    Species: Human
    Sample Types: Serum
  20. Soluble Urokinase Plasminogen Activator Receptor is Associated with Coronary Artery Calcification and Cardiovascular Disease in Patients Undergoing Hemodialysis
    Authors: W Wu, Y Cui, J Hu, R Liao, S Li, L Mo, L Xu, Y Chen, Z Lian, X Tian, Z Li, R Li, L Zhang, H Liang, J Ma, T Lin, Z Feng, W Dong, G Ke, P Ge, Z Ye, W Wang, B Zhang, W Shi, X Liang, S Liu
    Kidney Blood Press. Res., 2018;43(3):664-672.
    Species: Human
    Sample Types: Plasma
  21. PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway
    Authors: J Zhou, KJ Kwak, Z Wu, D Yang, J Li, M Chang, Y Song, H Zeng, LJ Lee, J Hu, C Bai
    Cell. Physiol. Biochem., 2018;47(5):1909-1924.
    Species: Human
    Sample Types: Cell Culture Supernates
  22. Soluble urokinase receptor (suPAR) predicts microalbuminuria in patients at risk for type 2 diabetes mellitus
    Authors: M Guthoff, R Wagner, E Randrianar, E Hatziagela, A Peter, HU Häring, A Fritsche, N Heyne
    Sci Rep, 2017;7(0):40627.
    Species: Human
    Sample Types: Serum
  23. Value of soluble Urokinase plasminogen activator receptor over age as a biomarker of impaired myocardial relaxation
    Authors: AS Koh, B Velmurugan, F Gao, RS Tan, JI Wong, LLY Teo, BMH Keng, SJM Chua, JM Yuan, WP Koh, C Cheung
    BMC Geriatr, 2017;17(1):275.
    Species: Human
    Sample Types: Plasma
  24. Soluble Urokinase Receptor Levels Are Correlated with Focal Segmental Glomerulosclerosis Lesions in IgA Nephropathy: A Cohort Study from China.
    Authors: Guo S, Han M, Chen M, Ning Y, Pei G, Li Y, Dai W, Ge S, Deng Y, Guo Y, Li X, Haller H, Xu G, Rong S
    PLoS ONE, 2015;10(9):e0138718.
    Species: Human
    Sample Types: Plasma
  25. Soluble urokinase receptor is a biomarker of cardiovascular disease in chronic kidney disease.
    Authors: Meijers B, Poesen R, Claes K, Dietrich R, Bammens B, Sprangers B, Naesens M, Storr M, Kuypers D, Evenepoel P
    Kidney Int, 2015;87(1):210-6.
    Species: Human
    Sample Types: Serum
  26. Plasma Soluble Urokinase Receptor Level Is Correlated with Podocytes Damage in Patients with IgA Nephropathy.
    Authors: Zhao Y, Liu L, Huang J, Shi S, Lv J, Liu G, Zhao M, Zhang H
    PLoS ONE, 2015;10(7):e0132869.
    Species: Human
    Sample Types: Plasma
  27. A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease.
    Authors: Spinale J, Mariani L, Kapoor S, Zhang J, Weyant R, Song P, Wong H, Troost J, Gadegbeku C, Gipson D, Kretzler M, Nihalani D, Holzman L
    Kidney Int, 2015;87(3):564-74.
    Species: Human
    Sample Types: Plasma
  28. Soluble Urokinase Receptor Is Released Selectively by Glioblastoma Cells That Express Epidermal Growth Factor Receptor Variant III and Promotes Tumor Cell Migration and Invasion.
    Authors: Gilder A, Jones K, Hu J, Wang L, Chen C, Carter B, Gonias S
    J Biol Chem, 2015;290(24):14798-809.
    Species: Human
    Sample Types: Serum
  29. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
    Authors: Lane D, Matte I, Garde-Granger P, Laplante C, Carignan A, Rancourt C, Piche A
    BMC Cancer, 2015;15(0):492.
    Species: Human
    Sample Types: Peritoneal Fluid
  30. Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children.
    Authors: Sinha, Aditi, Bajpai, Jaya, Saini, Savita, Bhatia, Divya, Gupta, Aarti, Puraswani, Mamta, Dinda, Amit K, Agarwal, Sanjay K, Sopory, Shailaja, Pandey, Ravindra, Hari, Pankaj, Bagga, Arvind
    Kidney Int, 2014;85(3):649-58.
    Species: Human
    Sample Types: Serum
  31. p-Cresol affects reactive oxygen species generation, cell cycle arrest, cytotoxicity and inflammation/atherosclerosis-related modulators production in endothelial cells and mononuclear cells.
    Authors: Chang M, Chang H, Chan C, Yeung S, Hsien H, Lin B, Yeh C, Tseng W, Tseng S, Jeng J
    PLoS ONE, 2014;9(12):e114446.
    Species: Human
    Sample Types: Whole Cells
  32. Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis.
    Authors: Huang J, Liu G, Zhang Y, Cui Z, Wang F, Liu X, Chu R, Zhao M
    BMC Med, 2014;12(0):81.
    Species: Human
    Sample Types: Urine
  33. Serum-soluble urokinase receptor concentration in primary FSGS.
    Authors: Maas RJ, Wetzels JF, Deegens JK
    Kidney Int., 2012;81(10):1043-4.
    Species: Human
    Sample Types: Serum
  34. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis.
    Authors: Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, Maiguel D, Karumanchi SA, Yap HK, Saleem M, Zhang Q, Nikolic B, Chaudhuri A, Daftarian P, Salido E, Torres A, Salifu M, Sarwal MM, Schaefer F, Morath C, Schwenger V, Zeier M, Gupta V, Roth D, Rastaldi MP, Burke G, Ruiz P, Reiser J
    Nat. Med., 2011;17(8):952-60.
    Species: Human
    Sample Types: Serum
  35. Identification of regulatory Hck and PAI-2 proteins in the monocyte response to PEG-containing matrices.
    Authors: Zuckerman ST, Brown JF, Kao WJ
    Biomaterials, 2009;30(23):3825-33.
    Species: Human
    Sample Types: Cell Culture Supernates
  36. The human airway trypsin-like protease modulates the urokinase receptor (uPAR, CD87) structure and functions.
    Authors: Beaufort N, Leduc D, Eguchi H, Mengele K, Hellmann D, Masegi T, Kamimura T, Yasuoka S, Fend F, Chignard M, Pidard D
    Am. J. Physiol. Lung Cell Mol. Physiol., 2007;292(5):L1263-72.
    Species: Human
    Sample Types: Cell Culture Supernates
  37. Urokinase-type plasminogen activator modulates airway eosinophil adhesion in asthma.
    Authors: Brooks AM, Bates ME, Vrtis RF, Jarjour NN, Bertics PJ, Sedgwick JB
    Am. J. Respir. Cell Mol. Biol., 2006;35(4):503-11.
    Species: Human
    Sample Types: BALF
  38. Low oxygen concentrations inhibit trophoblast cell invasion from early gestation placental explants via alterations in levels of the urokinase plasminogen activator system.
    Authors: Lash GE, Otun HA, Innes BA, Bulmer JN, Searle RF, Robson SC
    Biol. Reprod., 2005;74(2):403-9.
    Species: Human
    Sample Types: Cell Culture Supernates
  39. The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression.
    Authors: Wang J, Stockton DW, Ittmann M
    Clin. Cancer Res., 2004;10(18):6169-78.
    Species: Human
    Sample Types: Cell Lysates
  40. Pretreatment determination of the serum urokinase plasminogen activator and its soluble receptor in advanced small-cell lung cancer or non-small-cell lung cancer.
    Authors: Cobos E, Jumper C, Lox C
    Clin. Appl. Thromb. Hemost., 2003;9(3):241-6.
    Species: Human
    Sample Types: Serum
  41. Soluble urokinase-type plasminogen activator receptor (suPAR) as an independent factor predicting worse prognosis and extra-bone marrow involvement in multiple myeloma patients.
    Authors: Rigolin GM, Tieghi A, Ciccone M, Bragotti LZ, Cavazzini F, Della Porta M, Castagnari B, Carroccia R, Guerra G, Cuneo A, Castoldi G
    Br. J. Haematol., 2003;120(6):953-9.
    Species: Human
    Sample Types: Serum
  42. The circulating urokinase plasminogen activator (uPA) and its soluble receptor (suPAR) are not up-regulated by the circulating P105 fraction of the HER-2/neu proto-oncogene: in vivo evidence from patients with advanced non-small cell lung cancer (NSCLC).
    Authors: Jumper C, 107301, Cobos E, Lox C
    Anticancer Res., 2002;22(4):2073-6.
    Species: Human
    Sample Types: Serum


No product specific FAQs exist for this product, however you may

View all ELISA FAQs

Reviews for Human uPAR Quantikine ELISA Kit

There are currently no reviews for this product. Be the first to review Human uPAR Quantikine ELISA Kit and earn rewards!

Have you used Human uPAR Quantikine ELISA Kit?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review